Regeneron Pharmaceuticals, Inc. (REGN), Thursday announced that the U.S. Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application for EYLEA HD (aflibercept) Injection 8 mg for the treatment of retinal vein occlusion.
The FDA target action date is August 19, 2025, following the use of a Priority Review voucher, the company added.
The application seeks approval for two areas - treatment of macular edema following retinal vein occlusion, and for broadening the dosing schedule to include every 4-week (monthly) dosing across approved indications.
If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period, reducing the number of injections by half compared to all other anti-VEGF therapies.
The application is backed by data from across the EYLEA HD clinical program, including the Phase 3 QUASAR trial, which met its primary endpoint at 36 weeks.
In the pre-market hours, Regeneron's stock is trading at $547.72, down 0.28 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.